vimarsana.com

Latest Breaking News On - Kidney cancer research program - Page 1 : vimarsana.com

ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.

In Kidney Cancer Treatment, Personalized Biomarkers Work

Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

BAP1-Mutated RCC Responds to Treatment with Lynparza

Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.

Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC

Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.